Erik van den Berg, AM-Pharma CEO
AM-Pharma flies white flag on PhIII battle, but they aren't giving up on their kidney drug
The Dutch biotech AM-Pharma lost the Phase III battle on kidney disease, but they’re still fighting the long regulatory war.
The biotech put out word …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
